Zenas BioPharma is trading at a sharp discount to where its own analysts think it should be, and this week's 19% price drop has made that gap wider, not narrower. The most striking development came on the final day of the quarter. Citigroup's Yigal Nochomovitz raised his price target on ZBIO to $48 from $41 while maintaining a Buy rating, a vote of confidence delivered into a…
Key data as of 10 Nov 2026
Zenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash. Short sellers have dramatically…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZBIO — free to start on ORTEX.
Sign up for free →Open ZBIO on ORTEX